BR0115447A - Inibidores de tripeptìdeo de hepatite c - Google Patents

Inibidores de tripeptìdeo de hepatite c

Info

Publication number
BR0115447A
BR0115447A BR0115447-8A BR0115447A BR0115447A BR 0115447 A BR0115447 A BR 0115447A BR 0115447 A BR0115447 A BR 0115447A BR 0115447 A BR0115447 A BR 0115447A
Authority
BR
Brazil
Prior art keywords
hepatitis
tripeptide
analogs
inhibitors
tripeptide inhibitors
Prior art date
Application number
BR0115447-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Jeffrey Allen Campbell
Andrew Good
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0115447A publication Critical patent/BR0115447A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Treating Waste Gases (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
BR0115447-8A 2000-11-20 2001-11-20 Inibidores de tripeptìdeo de hepatite c BR0115447A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24996800P 2000-11-20 2000-11-20
PCT/US2001/045145 WO2002060926A2 (en) 2000-11-20 2001-11-20 Hepatitis c tripeptide inhibitors

Publications (1)

Publication Number Publication Date
BR0115447A true BR0115447A (pt) 2005-10-18

Family

ID=22945765

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115447-8A BR0115447A (pt) 2000-11-20 2001-11-20 Inibidores de tripeptìdeo de hepatite c

Country Status (14)

Country Link
US (1) US6872805B2 (US06780888-20040824-C00057.png)
EP (1) EP1337550B1 (US06780888-20040824-C00057.png)
JP (1) JP3889708B2 (US06780888-20040824-C00057.png)
CN (1) CN100391967C (US06780888-20040824-C00057.png)
AT (1) ATE327246T1 (US06780888-20040824-C00057.png)
AU (1) AU2002248147B2 (US06780888-20040824-C00057.png)
BR (1) BR0115447A (US06780888-20040824-C00057.png)
CA (1) CA2429359A1 (US06780888-20040824-C00057.png)
DE (1) DE60119968T2 (US06780888-20040824-C00057.png)
ES (1) ES2263687T3 (US06780888-20040824-C00057.png)
HU (1) HUP0500456A3 (US06780888-20040824-C00057.png)
MX (1) MXPA03004299A (US06780888-20040824-C00057.png)
PE (1) PE20020707A1 (US06780888-20040824-C00057.png)
WO (1) WO2002060926A2 (US06780888-20040824-C00057.png)

Families Citing this family (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2314598A1 (en) 1996-10-18 2011-04-27 Vertex Pharmaceuticals Incorporated Inhibitors of Hepatitis C virus NS3 serine protease
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
JP4299540B2 (ja) * 2001-01-23 2009-07-22 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｃ型肝炎ウイルスレプリコンおよびレプリコン増強細胞
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
AU2003260578A1 (en) * 2002-04-04 2003-10-20 Achillion Pharmaceuticals, Inc. Hcv antiviral and cytotoxicity drug screening assay
NZ561851A (en) 2002-04-11 2009-05-31 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
WO2003087119A1 (en) * 2002-04-12 2003-10-23 Achillion Pharmaceuticals, Inc. METHOD FOR SYNTHESIZING β-L-FLUORO-2´,3´DIDEHYDROCYTIDINE (β-L-FD4C)
US6869964B2 (en) 2002-05-20 2005-03-22 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis C virus inhibitors
WO2004043339A2 (en) * 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
JP4312718B2 (ja) 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
PT1523489E (pt) 2002-06-28 2014-06-24 Centre Nat Rech Scient Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
WO2004094452A2 (en) 2003-04-16 2004-11-04 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
ATE378334T1 (de) * 2003-05-21 2007-11-15 Boehringer Ingelheim Int Verbindungen als hepatitis c inhibitoren
PL3521297T3 (pl) 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
WO2005009418A2 (en) 2003-07-25 2005-02-03 Idenix (Cayman) Limited Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
PE20050374A1 (es) 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
NZ546663A (en) 2003-10-10 2010-01-29 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) * 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) * 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
ATE495185T1 (de) 2004-01-21 2011-01-15 Boehringer Ingelheim Int Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
AR047793A1 (es) 2004-01-30 2006-02-22 Medivir Ab Inhibidores de la serina proteasa ns-3 del vhc
JP2008505849A (ja) 2004-02-04 2008-02-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特に、ｈｃｖ、ｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
DK1718608T3 (da) 2004-02-20 2013-10-14 Boehringer Ingelheim Int Virale polymeraseinhibitorer
AP2006003763A0 (en) * 2004-03-30 2006-10-31 Intermune Inc Macrocyclic compounds as inhibitors of viral replication
WO2006000085A1 (en) 2004-06-28 2006-01-05 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
KR20070034119A (ko) * 2004-07-16 2007-03-27 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
UY29016A1 (es) * 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
ATE512971T1 (de) * 2004-07-20 2011-07-15 Boehringer Ingelheim Int Peptidanaloga als hepatitis c-hemmer
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008511633A (ja) * 2004-08-27 2008-04-17 シェーリング コーポレイション Ｃ型肝炎ウィルスｎｓ３セリンプロテアーゼの阻害因子としてのアシルスルホンアミド化合物
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7323447B2 (en) * 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA016071B1 (ru) 2005-05-13 2012-01-30 Вирокем Фарма Инк. Соединения и способы лечения или предотвращения флавивирусных инфекций
RU2427372C2 (ru) 2005-06-17 2011-08-27 Новартис Аг Применение санглиферина для лечения вируса гепатита с
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) * 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
EP1910378B1 (en) * 2005-07-20 2012-06-20 Boehringer Ingelheim International GmbH Hepatitis c inhibitor peptide analogs
CN102816170A (zh) 2005-07-25 2012-12-12 因特蒙公司 C型肝炎病毒复制的新颖大环抑制剂
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
WO2007016589A2 (en) 2005-08-02 2007-02-08 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8076365B2 (en) 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2007022459A2 (en) 2005-08-19 2007-02-22 Vertex Pharmaceuticals Incorporated Processes and intermediates
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AU2006301966A1 (en) 2005-10-11 2007-04-19 Array Biopharma, Inc. Compounds and methods for inhibiting hepatitis C viral replication
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
CA2629343A1 (en) 2005-11-11 2007-05-24 Vertex Pharmaceuticals, Inc. Hepatitis c virus variants
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2340836A1 (en) 2006-02-27 2011-07-06 Vertex Pharmceuticals Incorporated Co-crystals comprising VX-950 and their pharmaceutical compositions
BRPI0709567A2 (pt) 2006-03-16 2011-07-12 Vertex Pharma inibidores deuterados de protease de hepatite c
MX2008013119A (es) 2006-04-11 2008-10-21 Novartis Ag Inhibidores de hcv/vih y sus usos.
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
DK2041156T3 (en) 2006-07-13 2014-02-24 Achillion Pharmaceuticals Inc 4-AMINO-4-OXOBUTANOYL Peptides AS INHIBITORS OF VIRUS REPLICATION
WO2008019289A2 (en) * 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
CN101506167A (zh) 2006-08-17 2009-08-12 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2007321677B2 (en) 2006-11-15 2013-04-11 Vertex Pharmaceuticals (Canada) Incorporated Thiophene analogues for the treatment or prevention of flavivirus infections
WO2008070358A2 (en) * 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008074035A1 (en) * 2006-12-27 2008-06-19 Abbott Laboratories Hcv protease inhibitors and uses thereof
EP2125113A2 (en) 2007-02-26 2009-12-02 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
AU2008219704A1 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
GEP20125645B (en) * 2007-02-27 2012-09-25 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
CA2696053A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2008137126A2 (en) 2007-05-04 2008-11-13 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of hcv infection
EP2185524A1 (en) * 2007-05-10 2010-05-19 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
WO2009005677A2 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
EA019749B1 (ru) 2007-06-29 2014-06-30 Джилид Сайэнс, Инк. Противовирусные соединения
TW200918524A (en) * 2007-06-29 2009-05-01 Gilead Sciences Inc Antiviral compounds
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
CN101835774B (zh) 2007-08-30 2014-09-17 弗特克斯药品有限公司 共晶体和包含该共晶体的药物组合物
WO2009042668A2 (en) * 2007-09-24 2009-04-02 Achillion Pharmaceuticals, Inc. Urea-containing peptides as inhibitors of viral replication
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
CA2708042A1 (en) * 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Quinoxalinyl derivatives
MX2010006210A (es) 2007-12-05 2010-08-10 Enanta Pharm Inc Inhibidores de serina proteasa de hcv de tripeptido fluorado.
MX2010006313A (es) 2007-12-19 2010-06-25 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US9163061B2 (en) * 2007-12-21 2015-10-20 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
NZ586232A (en) 2007-12-21 2012-12-21 Avila Therapeutics Inc HCV protease inhibitors comprising a functionalised proline derivative
RU2490272C2 (ru) 2008-02-04 2013-08-20 Айденикс Фармасьютикалз, Инк. Макроциклические ингибиторы серинпротеазы
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
AU2009249443A1 (en) 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis C virus replication
US8163921B2 (en) * 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20090285774A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP5529120B2 (ja) 2008-05-29 2014-06-25 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010014134A1 (en) 2008-07-02 2010-02-04 Idenix Pharamaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP3025727A1 (en) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
WO2010045266A1 (en) * 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
CA2743912A1 (en) * 2008-11-20 2010-05-27 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
KR101762842B1 (ko) 2008-12-10 2017-08-04 아칠리온 파르마세우티칼스 인코포레이티드 바이러스 복제 억제제로서 유용한 신규한 4-아미노-4-옥소부타노일 펩티드
EA021794B1 (ru) * 2008-12-10 2015-09-30 Ачиллион Фармасьютикалз, Инк. Циклические аналоги 4-амино-4-оксобутаноил пептидов, ингибиторы репликации вирусов
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102300871A (zh) * 2008-12-19 2011-12-28 吉里德科学公司 Hcv ns3蛋白酶抑制剂
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
RU2011127080A (ru) 2009-01-07 2013-02-20 Сайнексис, Инк. Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
JP2012520884A (ja) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物
WO2010118009A1 (en) * 2009-04-06 2010-10-14 Ptc Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
MX2011012155A (es) 2009-05-13 2012-02-28 Enanta Pharm Inc Compuestos macrociclicos como inhibidores del virus de hepatitis c.
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
CN101921308A (zh) * 2009-06-16 2010-12-22 上海唐润医药科技有限公司 具有抗hcv活性的化合物及其用途
JP2013501068A (ja) 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
EP2483290A4 (en) * 2009-09-28 2013-05-01 Intermune Inc CYCLIC PEPTIC INHIBITORS FOR REPLICATION OF HEPATITIS C VIRUS
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
AU2010326225A1 (en) 2009-11-25 2012-06-07 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
AR079528A1 (es) 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
AU2010336355A1 (en) 2009-12-24 2012-07-05 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
AU2011232348A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
EP2550268A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119858A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119853A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
KR101715981B1 (ko) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 뉴클레오사이드 포스포르아미데이트
MX2012011222A (es) 2010-04-01 2013-01-18 Centre Nat Rech Scient Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
TWI516264B (zh) * 2010-05-06 2016-01-11 臺北醫學大學 芳香醯喹啉化合物
CA3240281A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
JP2013531011A (ja) 2010-06-28 2013-08-01 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
JP2013529684A (ja) 2010-06-28 2013-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
AU2011292040A1 (en) 2010-08-17 2013-03-07 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flaviviridae viral infections
EP3020723A1 (en) 2010-09-21 2016-05-18 Enanta Pharmaceuticals, Inc. Macrocyclic proline derived hcv serine protease inhibitors
BR112013008510A2 (pt) 2010-10-08 2016-07-05 Novartis Ag vitamina e formulações de inibidores de sulfamida ns3
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8937041B2 (en) 2010-12-30 2015-01-20 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
AU2011352145A1 (en) 2010-12-30 2013-07-18 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
JP2014514295A (ja) 2011-03-31 2014-06-19 アイディニックス ファーマシューティカルズ インコーポレイテッド ウイルス感染の治療のための化合物および薬学的組成物
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP6198721B2 (ja) * 2011-05-27 2017-09-20 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｈｃｖ感染症を治療するのに有用な置換されたアリファン、シクロファン、ヘテラファン、ヘテロファン、ヘテロ−ヘテラファンおよびメタロセン
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG187271A1 (en) * 2011-07-07 2013-02-28 Agency Science Tech & Res Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
WO2013016501A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Formulations of thiophene compounds
EP2755983B1 (en) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
CN103906759A (zh) 2011-09-12 2014-07-02 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
AU2012345732B2 (en) 2011-11-30 2016-07-14 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
AU2012347785B2 (en) 2011-12-06 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating viral diseases
US20130217644A1 (en) 2012-02-13 2013-08-22 Idenix Pharmaceuticals, Inc. Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
EA031301B1 (ru) 2012-05-22 2018-12-28 Иденикс Фармасьютикалз Ллс D-аминокислотные химические соединения для лечения заболеваний печени
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
MX353422B (es) 2012-10-08 2018-01-12 Idenix Pharmaceuticals Llc Análogos de 2'-cloronucleósido para infección por vhc.
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
WO2014063019A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
CN105164148A (zh) 2013-03-07 2015-12-16 百时美施贵宝公司 丙型肝炎病毒抑制剂
SG11201507469RA (en) 2013-03-14 2015-10-29 Achillion Pharmaceuticals Inc Processes for producing sovaprevir
MX2015013020A (es) 2013-03-15 2016-06-10 Achillion Pharmaceuticals Inc Polimorfos de sovaprevir y metodos de fabricacion de los mismos.
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
US20160271162A1 (en) 2013-11-01 2016-09-22 Idenix Pharmacueticals, Llc D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
US20170198005A1 (en) 2013-11-27 2017-07-13 Idenix Pharmaceuticals Llc 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
WO2015095419A1 (en) 2013-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 4'-or nucleosides for the treatment of hcv
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015134780A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors

Also Published As

Publication number Publication date
CN1531547A (zh) 2004-09-22
ES2263687T3 (es) 2006-12-16
WO2002060926A3 (en) 2003-03-13
WO2002060926A2 (en) 2002-08-08
HUP0500456A3 (en) 2012-05-02
DE60119968T2 (de) 2007-01-18
DE60119968D1 (en) 2006-06-29
MXPA03004299A (es) 2004-02-12
CA2429359A1 (en) 2002-08-08
US20020111313A1 (en) 2002-08-15
EP1337550A2 (en) 2003-08-27
ATE327246T1 (de) 2006-06-15
JP2004538251A (ja) 2004-12-24
EP1337550B1 (en) 2006-05-24
US6872805B2 (en) 2005-03-29
AU2002248147B2 (en) 2006-04-06
CN100391967C (zh) 2008-06-04
PE20020707A1 (es) 2002-08-11
HUP0500456A2 (hu) 2005-08-29
JP3889708B2 (ja) 2007-03-07

Similar Documents

Publication Publication Date Title
BR0115447A (pt) Inibidores de tripeptìdeo de hepatite c
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
IS7533A (is) Lifrarbólgu C-veirutálmar
DE60334205D1 (en) Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
NZ503263A (en) Hepatitis C NS3 protease inhibitor peptides and peptide analogues
BR0113666A (pt) Inibidores da protease peptidomimética
BR0112666A (pt) Peptìdeos como inibidores de ns3-serina protease de vìrus da hepatite c
ATE539744T1 (de) Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem
IL152022A0 (en) Compounds useful as protease inhibitors and pharmaceutical compositions containing the same
SG52628A1 (en) Substituted cyclic carbonyls and derivatives thereof useful as retrobiral protease inhibitors
HUP0400456A2 (hu) Hepatitis C vírus N-ciklikus P2 csoportokat tartalmazó makrociklusos NS3-szerin proteáz inhibitorai és ezeket tartalmazó gyógyszerkészítmények
UA66767C2 (uk) Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
BR0305259A (pt) Inibidores de hcv ns5b polimerase
TW200505944A (en) Crystalline phases of a potent HCV inhibitor
GB0011203D0 (en) Chemical compounds
DE69830751D1 (de) Polyaromatische Verbindungen zur Behandlung von Herpes-Infektionen
ATE493408T1 (de) Antiinfektiöse mittel
UY27030A1 (es) Inhibidores del virus de hepatitis c
DE60227101D1 (de) Dimere verbindungen und deren verwendung als antivirale mittel
ECSP003414A (es) Peptidos macrociclicos activos frente al virus de la hepatitis c

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]